Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer

CONCLUSION: We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.PMID:38330378 | DOI:10.3802/jgo.2024.35.e55

Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Takahiro Nozaki Ikuko Sakamoto Keiko Kagami Kenji Amemiya Yosuke Hirotsu Hitoshi Mochizuki Masao Omata Source Type: research